Complicated intra-abdominal infections: ceftolozane/tazobactam

This advice states that in a randomised controlled trial (RCT) in adults with complicated intra‑abdominal infections, intravenous ceftolozane/tazobactam plus metronidazole was found to be non‑inferior to intravenous meropenem plus saline (placebo) in terms of clinical cure rates 24–32 days after starting treatment. However, it is unclear whether the results apply to some populations; for example, people aged over 65 years, or those with renal impairment or who are at a higher risk of dying. Appendiceal perforation or abscess was the most common diagnosis in the study and less information is available on using ceftolozane/tazobactam in people with other diagnoses.

Source: Current Awareness Service for Health (CASH) - June 9, 2016 Category: Consumer Health News Source Type: news